Source - https://vandl-labs.com/?ref=connor If you can't find it on the site its cause its under GLP-RT - thats the reta lol What is Retatrutide? Retatrutide (LY-3437943) is a next-generation triple agonist peptide developed by Eli Lilly. It stimulates the GLP-1, GIP, and glucagon receptors simultaneously — making it more potent for fat loss, appetite suppression, and metabolic improvement compared to Semaglutide (Ozempic, Wegovy) or Tirzepatide (Mounjaro). Nicknames in the Community: - "The Triple Threat" - "Super GLP-1" - "Fat Loss Nuclear Bomb" Mechanism of Action - GLP-1 Agonist: Decreases appetite, slows gastric emptying, improves insulin sensitivity. - GIP Agonist: Enhances insulin secretion, promotes lean mass preservation. - Glucagon Agonist: Boosts energy expenditure, increases fat oxidation (unique feature). → Together = Eat Less + Burn More + Keep Muscle History and Development - 2022: Eli Lilly released Phase 1 trials showing insane weight loss (up to 24% of body weight over a year — unheard of levels). - 2023-2024: Ongoing Phase 2 trials confirm it outperforms Tirzepatide and Semaglutide. - Expected FDA Approval: Targeted for late 2025 (for obesity first, diabetes second). - Currently research chemical only — commonly sold through peptide clinics and underground labs. Ideal Users - People looking to drop 20+ pounds of fat relatively safely. - Advanced bodybuilders pre-contest needing extreme fat loss without major muscle loss. - High-performers wanting fast body recomposition without extreme starvation diets. Dosing Guide Starting Dose (note doses may vary based on individual need) Week Dose Notes 1 .5mg-1 / week Assess tolerance, reduce nausea risk. 2-3 2mg / week If side effects are manageable. 4-6 2.5-3mg / week Gradual increase for faster fat loss. 6+ 3-4mg / week (optional) Aggressive fat loss phase. Injection Frequency: - Once Weekly (Subcutaneous, same as Semaglutide or Tirzepatide). - Some biohackers split into twice-weekly to smooth out side effects (e.g., 1.5mg Monday, 1.5mg Thursday).